Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced paw edema at 40 mg/kg, po administered 3 hrs 30 mins after carrageenan-challenge measured after 60 mins (Rvb = 2.48 +/- 0.06 mL)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced paw edema at 20 mg/kg, po administered 3 hrs 30 mins after carrageenan-challenge measured after 60 mins (Rvb = 2.48 +/- 0.06 mL)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 40 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 120 mins (Rvb = 31.4 +/- 3.7 g)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 40 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 60 mins (Rvb = 33.9 +/- 3.7 g)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 40 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 30 mins (Rvb = 34.8 +/- 3.0 g)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 20 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 120 mins (Rvb = 31.4 +/- 3.7 g)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 20 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 60 mins (Rvb = 33.9 +/- 3.7 g)
Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 20 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 30 mins (Rvb = 34.8 +/- 3.0 g)
Antinociceptive activity in po dosed Swiss albino mouse assessed as reduction in number of acetic acid-induced writhing counted 5 mins after acetic acid challenge counted for 10 mins
Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction at 0.001 uM to 10 uM treated after KCl-challenge in presence of guanylate cyclase inhibitor 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction treated after KCl-challenge
Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction at 0.001 uM to 10 uM treated after KCl-challenge relative to control
Inhibition of arachidonic acid-induced COX1 activity in mouse J774 cells assessed as decrease in PGE2 levels incubated for 15 mins prior to arachidonic acid-challenge measured after 30 mins by RIA
Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as decrease in PGE2 production at 10 uM preincubated for 15 mins followed by substrate addition measured after 30 mins by radioimmunoassay relative to control
Inhibition of COX2 in Escherichia coli LPS-stimulated mouse J774 cells using arachidonic acid as substrate assessed as decrease in PGE2 production preincubated for 15 mins followed by substrate addition measured after 30 mins by radioimmunoassay
Induction of nitric oxide release in rat liver assessed as maximum nitrite levels at 1 mM after 4 hrs by amperometric method relative to sodium nitroprusside